CClinicalTrials.gg
CompletedNCT06679764Updated Jan 30, 2026Results posted

The Ultrasound Guided Pericapsular Nerve Group and Anterior Quadratus Lumborum Blocks in Hip Replacement Surgeries

A Phase 4 interventional study of Anterior quadratus lumborum block technique (AQLB) and Pericapsular Nerve Group (PENG) block in Post Operative Analgesia, sponsored by Cairo University. Completed at 1 site in Egypt. Open to participants aged Up to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Cairo University · Phase 4, Interventional, and Supportive care

From the registry’s dates

  • Registered 2 years 6 months after the study started (first participant enrolled May 2022, registered Nov 2024).
Phase
Phase 4
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
Up to 65 Years
Sex
All
01

Study summary

The investigators hypothesis that PENG block will produce effective opioid sparing analgesia with enhanced motor recovery more than AQLB in elderly patients undergoing total hip replacement surgeries

Read the detailed description

Aim of the work:

The aim of this study is to compare analgesic efficacy and motor recovery of the ultrasound guided anterior quadratus lumborum block and the pericapsular nerve group block

Statistical Analysis:

Data will be coded and entered using the statistical package SPSS version 22. Categorical data will be expressed frequency and proportion and will be compared by Chi2. Numerical data will be summarized using mean and standard deviation. Comparisons between groups for normally distributed data will be done using analysis of variance (ANOVA), while for non-normally distributed numeric variable will be done by Krauskal Wallis test. P value less than or equal to 0.05 will be considered statistically significant. All test will be two tailed

02

Conditions studied

  • Post Operative Analgesia
03

In context

Lead sponsor

Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Both genders
  • Type of surgery; unilateral elective total hip replacement.
  • Physical status ASA I- III
  • Age ≥ 65 Years.
  • Body mass index (BMI): > 20 kg/m2 and \< 35 kg/m2.
  • Traumatic fracture hip through anterolateral approach.

Exclusion criteria

Exclusion Criteria:

  • Patient refusal.
  • Patients with known sensitivity or contraindication to drugs used in the study (local anesthetics \& opioids).
  • History of psychological disorders and/or chronic pain.
  • Pre- existing peripheral neuropathies
  • Coagulopathy.
  • Infection of the skin at the site of needle puncture area.
  • Active cardiac condition (unstable coronary syndromes, significant arrhythmias, severe valvular disease).
  • Acute respiratory disease (active chest infection, respiratory failure).
  • Advanced liver disease (increased liver enzymes >3 folds) or severe kidney disease (creatinine >2).
  • long operative time more than 3 hours.
05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
93 participants (actual)

Study arms

  • Active comparator
    Anterior quadratus lumborum block technique (AQLB)

    AQLB performed in the lateral position. A low-frequency convex probe for the abdomen (2-5) MHz convex probe, (Siemens ACUSON X300 Ultrasound System) was placed horizontally above the iliac crest. On ultrasound, The psoas major was located on the ventral side of the transverse process, the erector spinae was located on the dorsal side of the transverse process, and the quadratus lumborum was located on the lateral side of the transverse process. A 38-mm 22-gauge regional block needle was advanced in-plane from posterior to anterior directing the needle tip in the fascial plane between the psoas major and the quadratus lumborum that was confirmed by injecting 1 ml saline and watchingt the fluil fting the muscle while not distending any of the two muscles (hydro-localization). Then 30mL of local anaesthetic (29ml of 0.25% bupivacaine + 1 ml of dexamethasone (4mgs) was injected with observation of local anaesthesia spread in the fascial plane.

    Procedure: Anterior quadratus lumborum block technique (AQLB)

  • Active comparator
    Pericapsular Nerve Group (PENG) block

    With the patients in supine position, A low-frequency convex probe (2-5 MHz) in was placed in a transverse plane over the anterior inferior iliac spine and then it was rotated 45 degrees in counter-clockwise direction to be aligned with the pubic ramus. In this view, the ilio-pubic eminence, iliopsoas muscle tendon, femoral nerve and vessels was observed. With in-plane approach, a 38-mm 22-gauge (22-G, 50-mm) regional block needle inserted in-plane, from lateral to medial to place the needle tip underneath the iliopsoas tendon, exactly between the ilipsoas fascia anteriorly and the pubic ramus posteriorly. Following negative resistance and aspiration tests, correct location of the needle tip was confirmed by injecting 1 ml saline. Then, 30mL of local anaesthetic (29ml of 0.25% bupivacaine+ 1ml of dexamethasone (4mgs) was injected while observing for adequate fluid spread.

    Procedure: Pericapsular Nerve Group (PENG) block

  • Active comparator
    Control Group

    Pataints received opioid analgesia with GA

    Drug: Control Group

Interventions

  • ProcedureAnterior quadratus lumborum block technique (AQLB)

    AQLB performed in the lateral position. A low-frequency convex probe for the abdomen (2-5) MHz convex probe, (Siemens ACUSON X300 Ultrasound System) was placed horizontally above the iliac crest. On ultrasound, The psoas major was located on the ventral side of the transverse process, the erector spinae was located on the dorsal side of the transverse process, and the quadratus lumborum was located on the lateral side of the transverse process. A 38-mm 22-gauge regional block needle was advanced in-plane from posterior to anterior directing the needle tip in the fascial plane between the psoas major and the quadratus lumborum that was confirmed by injecting 1 ml saline and watchingt the fluil fting the muscle while not distending any of the two muscles (hydro-localization). Then 30mL of local anaesthetic (29ml of 0.25% bupivacaine + 1 ml of dexamethasone (4mgs) was injected with observation of local anaesthesia spread in the fascial plane.

  • ProcedurePericapsular Nerve Group (PENG) block

    With the patients in supine position, A low-frequency convex probe (2-5 MHz) in was placed in a transverse plane over the anterior inferior iliac spine and then it was rotated 45 degrees in counter-clockwise direction to be aligned with the pubic ramus. In this view, the ilio-pubic eminence, iliopsoas muscle tendon, femoral nerve and vessels was observed. With in-plane approach, a 38-mm 22-gauge (22-G, 50-mm) regional block needle inserted in-plane, from lateral to medial to place the needle tip underneath the iliopsoas tendon, exactly between the ilipsoas fascia anteriorly and the pubic ramus posteriorly. Following negative resistance and aspiration tests, correct location of the needle tip was confirmed by injecting 1 ml saline. Then, 30mL of local anaesthetic (29ml of 0.25% bupivacaine+ 1ml of dexamethasone (4mgs) was injected while observing for adequate fluid spread.

  • DrugControl Group

    Pataints received opioid analgesia with genaral anesthesia

06

What researchers measure

Primary outcomes

  1. The Total Amount of Morphine Consumption

    Total dose of IV morphine (mg) administered as rescue analgesia during the first 24 postoperative hours. Morphine 0.05 mg/kg IV boluses were given when NRS ≥4, up to a maximum of 0.3 mg/kg/24 h. Reported as median (IQR).

    Time frame: Immediatly post operative for 24 hours

Secondary outcomes

  1. Numeric Pain Rating Scale at Rest Over First 24 Hours

    Pain intensity at rest using 0-10 Numeric Pain Rating Scale (0 = no pain, 10 = worst imaginable pain) measured at specified time points; data reported as median (IQR).

    Time frame: 30 minutes, 2, 4, 6, 8, 12, 18, and 24 hours after surgery

  2. Numeric Pain Rating Scale During Passive 90° Hip Flexion Over First 24 Hours

    Pain intensity during passive 90° hip flexion using 0-10 NRS at same time points; reported as median (IQR).

    Time frame: at 30 minutes, 2, 4, 6, 8, 12, 18 and 24 hours postoperatively

  3. Time to First Rescue Morphine Analgesia

    Time from arrival in PACU to first administration of IV morphine rescue dose (NRS ≥4). Reported as median (IQR).

    Time frame: Immediatly post operative for 24 hours

  4. Manual Muscle Test (MMT) Score for Quadriceps/Iliopsoas Over First 24 Hours

    Manual muscle test (0-5 scale; 0 = no contraction, 5 = full ROM against gravity and maximal resistance) for quadriceps and iliopsoas muscles on the operated side, after extubation, at predefined time points.

    Time frame: 30 minutes, 2, 4, 6, 8, 12, 18 and 24 hours postoperatively

  5. Active Hip Flexion Range of Motion (0°-90°) Over First 24 Hours

    Active hip flexion range of motion (degrees) of the operated hip, from 0° to 90°, assessed at same time points as MMTe. Reported as median (IQR).

    Time frame: 30 minutes, 2, 4, 6, 8, 12, 18 and 24 hours postoperatively

  6. Total Intraoperative Fentanyl Dose

    Total dose of IV fentanyl administered intraoperatively. Additional boluses of 1 μg/kg were given if MAP or HR increased by \>20% above baseline. Reported as mean ± SD.

    Time frame: During surgery

  7. Time to First Walk

    Time from end of surgery to first ambulation (≥3 steps with walker). Reported as median (IQR)

    Time frame: From end of surgery until first walk (within postoperative 24 h)

  8. Length of Hospital Stay

    Time from surgery to hospital discharge. Reported as mean ± SD.

    Time frame: From date of surgery until discharge

07

Results

Posted Jan 30, 2026
Limitations and caveats
Single-center study at a tertiary university hospital, which may limit generalizability. Pain and motor assessments are partly subjective. Follow-up was restricted to the first 24 postoperative hours; long-term functional outcomes and block-related complications beyond this period were not assessed.

Participant flow

Elderly patients (≥65 years) with traumatic hip fractures scheduled for elective unilateral total hip arthroplasty via an anterolateral approach under general anesthesia were recruited at the Orthopedic Surgical Theater, Cairo University Hospital. Recruitment occurred at a single tertiary university hospital in Egypt.

Participant flow — Overall Study
MilestoneAnterior Quadratus Lumborum Block Technique (AQLB)Pericapsular Nerve Group (PENG) BlockControl Group
Started313131
Completed313131
Not completed000

Outcome measures

PrimaryThe Total Amount of Morphine Consumption

Total dose of IV morphine (mg) administered as rescue analgesia during the first 24 postoperative hours. Morphine 0.05 mg/kg IV boluses were given when NRS ≥4, up to a maximum of 0.3 mg/kg/24 h. Reported as median (IQR).

Time frame:
Immediatly post operative for 24 hours
Reported as:
Median · mg of IV morphine
The Total Amount of Morphine Consumption
mg of IV morphineAnterior Quadratus Lumborum Block Technique (AQLB)Pericapsular Nerve Group (PENG) BlockControl Group
The Total Amount of Morphine Consumption6.0 (3.5 to 8.0)8.0 (6.0 to 11.0)12.0 (10.5 to 12.0)
Statistical analysis
  • Anterior Quadratus Lumborum Block Technique (AQLB) vs Pericapsular Nerve Group (PENG) Block vs Control Group · Kruskal-Wallis · p = 0.035 (Overall comparison of 24-h postoperative morphine consumption across the three groups used the Kruskal-Wallis test (non-parametric).)
SecondaryNumeric Pain Rating Scale at Rest Over First 24 Hours

Pain intensity at rest using 0-10 Numeric Pain Rating Scale (0 = no pain, 10 = worst imaginable pain) measured at specified time points; data reported as median (IQR).

Time frame:
30 minutes, 2, 4, 6, 8, 12, 18, and 24 hours after surgery
Reported as:
Median · units on a scale
Numeric Pain Rating Scale at Rest Over First 24 Hours
units on a scaleAnterior Quadratus Lumborum Block Technique (AQLB)Pericapsular Nerve Group (PENG) BlockControl Group
30 min0.0 (0.0 to 0.0)1.0 (0.0 to 1.0)2.0 (2.0 to 3.0)
2 h1.0 (0.0 to 1.0)1.0 (0.0 to 1.0)2.0 (1.0 to 6.0)
4 h1.0 (1.0 to 2.0)2.0 (0.0 to 2.0)3.0 (2.0 to 3.0)
6 h2.0 (1.0 to 2.0)2.0 (1.0 to 3.0)2.0 (1.0 to 3.0)
8 h2.0 (2.0 to 3.0)3.0 (2.0 to 4.0)3.0 (2.0 to 4.0)
12 h3.0 (2.0 to 3.0)3.0 (3.0 to 4.0)3.0 (2.0 to 3.0)
18 h3.0 (2.0 to 3.0)3.0 (3.0 to 4.0)3.0 (2.0 to 4.0)
24 h3.0 (3.0 to 3.0)3.0 (3.0 to 4.0)3.0 (2.0 to 3.0)
SecondaryNumeric Pain Rating Scale During Passive 90° Hip Flexion Over First 24 Hours

Pain intensity during passive 90° hip flexion using 0-10 NRS at same time points; reported as median (IQR).

Time frame:
at 30 minutes, 2, 4, 6, 8, 12, 18 and 24 hours postoperatively
Reported as:
Median · units on a scale
Numeric Pain Rating Scale During Passive 90° Hip Flexion Over First 24 Hours
units on a scaleAnterior Quadratus Lumborum Block Technique (AQLB)Pericapsular Nerve Group (PENG) BlockControl Group
30 min1.0 (1.0 to 1.0)1.0 (0.0 to 2.0)3.0 (3.0 to 3.0)
2 h2.0 (1.0 to 2.0)1.0 (0.0 to 2.0)5.0 (3.0 to 7.0)
4 h2.0 (2.0 to 3.0)2.0 (1.0 to 3.0)3.0 (3.0 to 4.0)
6 h3.0 (2.0 to 3.0)3.0 (1.0 to 3.0)3.0 (3.0 to 7.0)
8 h3.0 (3.0 to 3.0)3.0 (2.0 to 4.0)5.0 (3.0 to 6.0)
12 h3.0 (3.0 to 4.0)3.0 (3.0 to 4.0)3.0 (3.0 to 3.0)
18 h3.0 (3.0 to 4.0)4.0 (3.0 to 5.0)5.0 (4.0 to 7.0)
24 h3.0 (3.0 to 4.0)3.0 (3.0 to 4.0)3.0 (3.0 to 4.0)
SecondaryTime to First Rescue Morphine Analgesia

Time from arrival in PACU to first administration of IV morphine rescue dose (NRS ≥4). Reported as median (IQR).

Time frame:
Immediatly post operative for 24 hours
Reported as:
Median · Hours
Time to First Rescue Morphine Analgesia
HoursAnterior Quadratus Lumborum Block Technique (AQLB)Pericapsular Nerve Group (PENG) BlockControl Group
Time to First Rescue Morphine Analgesia12.0 (6.0 to 18.0)8.0 (7.0 to 12.0)2.0 (2.0 to 4.0)
SecondaryManual Muscle Test (MMT) Score for Quadriceps/Iliopsoas Over First 24 Hours

Manual muscle test (0-5 scale; 0 = no contraction, 5 = full ROM against gravity and maximal resistance) for quadriceps and iliopsoas muscles on the operated side, after extubation, at predefined time points.

Time frame:
30 minutes, 2, 4, 6, 8, 12, 18 and 24 hours postoperatively
Reported as:
Median · units on a scale
Manual Muscle Test (MMT) Score for Quadriceps/Iliopsoas Over First 24 Hours
units on a scaleAnterior Quadratus Lumborum Block Technique (AQLB)Pericapsular Nerve Group (PENG) BlockControl Group
30 min1.0 (0.0 to 1.0)2.0 (2.0 to 2.0)0.0 (0.0 to 2.0)
2 h1.0 (1.0 to 1.0)3.0 (3.0 to 3.0)1.0 (1.0 to 1.0)
4 h2.0 (2.0 to 2.0)3.0 (3.0 to 4.0)2.0 (2.0 to 3.0)
6 h2.0 (2.0 to 3.0)4.0 (4.0 to 4.0)3.0 (2.0 to 4.0)
8 h3.0 (3.0 to 3.0)4.0 (4.0 to 4.0)3.0 (3.0 to 4.0)
12 h3.0 (3.0 to 3.0)4.0 (4.0 to 4.0)4.0 (3.0 to 4.0)
18 h3.0 (3.0 to 4.0)4.0 (4.0 to 4.0)4.0 (4.0 to 4.0)
24 h4.0 (4.0 to 4.0)4.0 (4.0 to 4.0)4.0 (4.0 to 4.0)
SecondaryActive Hip Flexion Range of Motion (0°-90°) Over First 24 Hours

Active hip flexion range of motion (degrees) of the operated hip, from 0° to 90°, assessed at same time points as MMTe. Reported as median (IQR).

Time frame:
30 minutes, 2, 4, 6, 8, 12, 18 and 24 hours postoperatively
Reported as:
Median · Degrees of hip flexion
Active Hip Flexion Range of Motion (0°-90°) Over First 24 Hours
Degrees of hip flexionAnterior Quadratus Lumborum Block Technique (AQLB)Pericapsular Nerve Group (PENG) BlockControl Group
30 min0.0 (0.0 to 0.0)20.0 (10.0 to 20.0)0.0 (0.0 to 10.0)
2 h0.0 (0.0 to 0.0)30.0 (20.0 to 45.0)20.0 (0.0 to 20.0)
4 h0.0 (0.0 to 20.0)45.0 (30.0 to 45.0)30.0 (20.0 to 45.0)
6 h0.0 (0.0 to 20.0)45.0 (45.0 to 45.0)45.0 (30.0 to 45.0)
8 h30.0 (20.0 to 45.0)90.0 (45.0 to 90.0)45.0 (30.0 to 45.0)
12 h45.0 (45.0 to 45.0)90.0 (90.0 to 90.0)45.0 (45.0 to 60.0)
18 h45.0 (45.0 to 45.0)90.0 (90.0 to 90.0)45.0 (45.0 to 60.0)
24 h90.0 (45.0 to 90.0)90.0 (90.0 to 90.0)45.0 (45.0 to 90.0)
SecondaryTotal Intraoperative Fentanyl Dose

Total dose of IV fentanyl administered intraoperatively. Additional boluses of 1 μg/kg were given if MAP or HR increased by \>20% above baseline. Reported as mean ± SD.

Time frame:
During surgery
Reported as:
Mean · μg fentanyl
Total Intraoperative Fentanyl Dose
μg fentanylAnterior Quadratus Lumborum Block Technique (AQLB)Pericapsular Nerve Group (PENG) BlockControl Group
Total Intraoperative Fentanyl Dose142.58 ± 18.43152.90 ± 60.23236.61 ± 90.68
SecondaryTime to First Walk

Time from end of surgery to first ambulation (≥3 steps with walker). Reported as median (IQR)

Time frame:
From end of surgery until first walk (within postoperative 24 h)
Reported as:
Median · Hours
Time to First Walk
HoursAnterior Quadratus Lumborum Block Technique (AQLB)Pericapsular Nerve Group (PENG) BlockControl Group
Time to First Walk24.0 (18.0 to 24.0)8.0 (8.0 to 12.0)18.0 (12.0 to 24.0)
SecondaryLength of Hospital Stay

Time from surgery to hospital discharge. Reported as mean ± SD.

Time frame:
From date of surgery until discharge
Reported as:
Mean · Days
Length of Hospital Stay
DaysAnterior Quadratus Lumborum Block Technique (AQLB)Pericapsular Nerve Group (PENG) BlockControl Group
Length of Hospital Stay3.16 ± 0.522.13 ± 0.342.94 ± 0.68

Adverse events

Collected over Intraoperative period and first 24 postoperative hours through discharge up to 4 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Anterior Quadratus Lumborum Block Technique (AQLB)0/31 (0%)0/31 (0%)0/31 (0%)
Pericapsular Nerve Group (PENG) Block0/31 (0%)0/31 (0%)0/31 (0%)
Control Group0/31 (0%)0/31 (0%)7/31 (22.6%)
Most frequent other events
Most frequent other events
EventAnterior Quadratus Lumborum Block Technique (AQLB)Pericapsular Nerve Group (PENG) BlockControl Group
Postoperative nausea and vomitingGastrointestinal disorders0/310/317/31

Baseline characteristics

Baseline characteristics were obtained for all randomized participants in each arm (31 per group), with no exclusions.

Age, Categorical
Age, Categorical(Participants)Anterior Quadratus Lumborum Block Technique (AQLB)Pericapsular Nerve Group (PENG) BlockControl GroupTotal
<=18 years0000
Between 18 and 65 years0000
>=65 years31313193
Sex: Female, Male
Sex: Female, Male(Participants)Anterior Quadratus Lumborum Block Technique (AQLB)Pericapsular Nerve Group (PENG) BlockControl GroupTotal
Female17181247
Male14131946
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Anterior Quadratus Lumborum Block Technique (AQLB)Pericapsular Nerve Group (PENG) BlockControl GroupTotal
Count of participants———0
Region of Enrollment
Region of Enrollment(Participants)Anterior Quadratus Lumborum Block Technique (AQLB)Pericapsular Nerve Group (PENG) BlockControl GroupTotal
Egypt31313193
Age
Age(years)Anterior Quadratus Lumborum Block Technique (AQLB)Pericapsular Nerve Group (PENG) BlockControl GroupTotal
Median68.74 ± 3.3270.87 ± 4.7469.55 ± 2.5969.72 ± 3.73
08

Study locations

1 site
  • Faculty of Medicine, Cairo University
    Cairo, Egypt
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Mar 16, 2022

Documents are hosted by the registry — open the source record to download them.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06679764
Lead sponsor
Cairo University
Responsible party
Mohamed Youssef (Assistant Professor, Cairo University) — Principal investigator
First posted
Nov 7, 2024
Start date
May 1, 2022
Primary completion
Sep 15, 2023
Completion
Jan 31, 2024
Results posted
Jan 30, 2026
Last update
Jan 30, 2026

Study contacts

Mohamed A Ollaek, MD
principal investigator · Cairo University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion